It is noted that in this pooled analysis, the rate of T790M positivity did not differ between Asian and non-Asian patients, which suggests that the source of the variation between this study and ours is likely not the difference in ethnic background, and could at least partly be attributable to different tumor burden and number of prior treatment lines received by the patients, as all patients in our study had received EGFR-TKI in the first-line setting, whereas in the AURA trials patients could have received more than one prior line of therapy [46]. The gene discussed is EGFR; the disease is neoplasm.